Sun Pharma’s Aggrenox gets USFDA nod
24 August 2018 | News
This is a generic copy of Boehringer Ingelheim Pharma’s drug Aggrenox (Aspirin/Dipyridamole). Aggrenox and its generics are estimated to have US sales of ~$230mn in the US
Sun Pharma has received final USFDA approval for Aspirin and Dipyridamole. This is a generic copy of Boehringer Ingelheim Pharma’s drug Aggrenox.
Aggrenox is used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot.
Aggrenox and its generics are estimated to have US sales of approximately $230mn in the US and with the lower competition, Sun pharma expect to make $8-10mn/annum from this drug.
